MedPath

ELEISON PHARMACEUTICALS LLC

🇺🇸United States
Ownership
-
Employees
-
Market Cap
-
Website

Clinical Trials

4

Active:0
Completed:2

Trial Phases

2 Phases

Phase 2:3
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (4 trials with phase data)• Click on a phase to view related trials

Phase 2
3 (75.0%)
Phase 3
1 (25.0%)

Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer

Phase 3
Recruiting
Conditions
Metastatic Pancreatic Adenocarcinoma
Interventions
First Posted Date
2013-10-07
Last Posted Date
2024-12-31
Lead Sponsor
Eleison Pharmaceuticals LLC.
Target Recruit Count
480
Registration Number
NCT01954992
Locations
🇺🇸

Innovative Clinical Research Institute, Whittier, California, United States

🇺🇸

Moffitt Cancer Center, Tampa, Florida, United States

🇺🇸

Gabrail Cancer Center Research, Canton, Ohio, United States

Phase 2 Study of Inhaled Lipid Cisplatin in Pulmonary Recurrent Osteosarcoma

Phase 2
Completed
Conditions
Pulmonary Relapse of Osteosarcoma
Interventions
Drug: Inhaled Lipid Cisplatin (ILC)
First Posted Date
2012-07-26
Last Posted Date
2019-08-07
Lead Sponsor
Eleison Pharmaceuticals LLC.
Target Recruit Count
28
Registration Number
NCT01650090
Locations
🇺🇸

Children's Hospital Los Angeles, Los Angeles, California, United States

🇺🇸

Stanford University Medical Center, Palo Alto, California, United States

🇺🇸

H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 12 locations

Safety and Efficacy Study of Glufosfamide in Ovarian Cancer

Phase 2
Terminated
Conditions
Ovarian Cancer
Interventions
First Posted Date
2007-03-02
Last Posted Date
2015-03-10
Lead Sponsor
Eleison Pharmaceuticals LLC.
Target Recruit Count
17
Registration Number
NCT00442598
Locations
🇺🇸

Premiere Oncology of Arizona, Scottsdale, Arizona, United States

🇺🇸

Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

California Cancer Center, Greenbrae, California, United States

and more 7 locations

Safety and Efficacy Study of Glufosfamide in Previously Treated Advanced Soft Tissue Sarcoma

Phase 2
Completed
Conditions
Soft Tissue Sarcoma
Interventions
First Posted Date
2007-03-01
Last Posted Date
2015-03-25
Lead Sponsor
Eleison Pharmaceuticals LLC.
Target Recruit Count
22
Registration Number
NCT00441467
Locations
🇺🇸

Premiere Oncology of Arizona, Scottsdale, Arizona, United States

🇺🇸

Arizona Cancer Center, Tucson, Arizona, United States

🇺🇸

Stanford Cancer Center, Stanford, California, United States

and more 4 locations

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.